Vasa Therapeutics – a preclinical stage biopharmaceutical company developing novel therapies for cardiovascular aging – recently announced the closing of $6 million in series seed funding led by Orphinic Scientific SA. The funding round also included participation from private investment funds NuFund Venture Group, SeedFolio, and others.
Orphinic’s chairman of the supervisory board, Prof. Jarosław Leszczyszyn, will join Vasa’s board of directors and represent this round of seed investors.
Pillsbury Winthrop Shaw Pittman LLP served as legal counsel to Vasa.
KEY QUOTES:
“We are delighted to gain support from a high-quality group of US and international investors who share Vasa’s mission to develop transformative therapies for cardiovascular aging that could extend the healthy lifespan. This closing comes at an exciting time for Vasa as VS-041, our clinical candidate for heart failure with preserved ejection fraction (HFpEF), enters the final stages of preclinical development with favorable FDA feedback at a recent pre-IND meeting.”
— Artur Plonowski, MD, PhD, CEO and Co-founder of Vasa
“We are excited to have led the seed financing for Vasa. The company’s novel biomarker strategy can lead to a personalized medicine-based therapy for HFpEF, a highly heterogenous disease, for which the currently available drugs do not provide durable improvement. We are also pleased to see multiple opportunities for the other Vasa assets, including sarcopenia, obesity, and peripheral artery disease.”
— Adam Kruszewski, CEO of Orphinic
